Sotera Health Company

SHC

Equity

ISIN US83601L1026 / Valor 57897071

NASDAQ (2024-09-17)

USD 16.66-1.48%

Sotera Health Company
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sotera Health Company is a global leader in providing end-to-end sterilization solutions and lab testing services for the healthcare industry. Through its three best-in-class businesses - Sterigenics, Nordion, and Nelson Labs - the company offers outsourced terminal sterilization, irradiation services, microbiological and analytical chemistry testing, and Cobalt-60 supply. With over 90 years of expertise and operations in 13 countries, Sotera Health ensures the safety and quality of medical devices, pharmaceuticals, and food safety products through its comprehensive range of services.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first quarter of 2024, Sotera Health Company reported a 12.5% increase in net revenues, reaching $248 million compared to $221 million in the same quarter of 2023. This growth was driven by favorable pricing and changes in foreign currency exchange rates.

Net Income

Sotera Health Company's net income for the first quarter of 2024 was $6 million, or $0.02 per diluted share. This represents a significant improvement from the net income of $3 million, or $0.01 per diluted share, reported in the first quarter of 2023.

Adjusted EBITDA

For the first quarter of 2024, Sotera Health Company achieved an Adjusted EBITDA of $112 million, marking a 13.7% increase compared to the same period in 2023. This growth reflects the company's strong operational performance and effective cost management.

Adjusted EPS

Sotera Health Company's Adjusted Earnings Per Diluted Share (Adjusted EPS) for the first quarter of 2024 remained flat at $0.13, the same as in the first quarter of 2023. This stability indicates consistent profitability despite market challenges.

2024 Outlook

Sotera Health Company has reaffirmed its 2024 outlook, anticipating net revenues and Adjusted EBITDA growth in the range of 4.0% to 6.0%. The company also expects Adjusted EPS to be between $0.67 and $0.75, maintaining a positive outlook for the remainder of the year.

Summarized from source with an LLMView Source

Key figures

7.14%1Y

-34.0%3Y

%5Y

Performance

38.0%1Y

66.2%3Y

61.5%5Y

Volatility